Alto Neuroscience, Inc. (ANRO) shareholders
Close on Nov 17, 2026Market cap $977.52MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC Joint filing with Joseph Edelman (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 4,176,711 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Alpha Wave Ventures GP, Ltd Joint filing with Alpha Wave Global, LP (13.80%), Chimera Investment LLC (13.80%) and 1 more | 3,707,757 | 13.80% | 13G (passive) | Feb 6, 2024 |
| Robert Egen Atkinson Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more | 3,588,180 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 3,249,934 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Commodore Capital Master LP Joint filing with Commodore Capital LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more | 3,245,628 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (9.80%), Robert Egen Atkinson (9.80%) and 1 more | 3,190,267 | 9.80% | 13G (passive) | Oct 20, 2025 |
| EcoR1 Capital, LLC Joint filing with Oleg Nodelman (5.80%), EcoR1 Capital Fund Qualified, L.P. (5.30%) | 2,232,000 | 5.80% | 13G (passive) | Jul 13, 2026 |
| Alex Silverstein Joint filing with Sirenia Capital Management LP (6.20%) | 2,219,568 | 6.20% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 2,104,406 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (7.30%), Joseph Edelman (7.30%) | 1,989,393 | 7.30% | 13G (passive) | Oct 3, 2025 |
| Vanguard Capital Management | 1,970,108 | 5.02% | 13G (passive) | Sep 30, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (6.00%) | 1,624,000 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| Parag Shah Joint filing with K2 HealthVentures Equity Trust LLC (5.60%), Anup Arora (5.60%) | 1,617,855 | 5.60% | 13G (passive) | Jan 13, 2025 |
| Amit Etkin | 1,461,130 | 5.40% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANRO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Alpha Wave Global, LP | 3,707,757 | 9.45% | $97.85M | – | 1.57% |
| Commodore Capital LP | 2,723,196 | 6.94% | $71.87M | – | 4.28% |
| BlackRock, Inc. | 2,121,009 | 5.40% | $55.97M | +1,454,821 | 0.00% |
| Perceptive Advisors LLC | 1,609,893 | 4.10% | $42.49M | −400,000 | 0.64% |
| Adage Capital Partners Gp, L.L.C. | 1,600,000 | 4.08% | $42.22M | +1,215,000 | 0.06% |
| Vanguard Capital Management LLC | 1,389,477 | 3.54% | $36.67M | +182,452 | 0.00% |
| Spruce Street Capital LP | 1,353,047 | 3.45% | $35.71M | +27,837 | 7.01% |
| Vivo Capital, LLC | 1,208,858 | 3.08% | $31.90M | +173,307 | 2.91% |
| Franklin Resources Inc | 1,013,307 | 2.58% | $26.74M | −88,567 | 0.01% |
| Armistice Capital, LLC | 864,000 | 2.20% | $22.80M | −48,000 | 0.28% |
| Affinity Asset Advisors, LLC | 850,000 | 2.17% | $22.43M | +350,000 | 1.01% |
| Vestal Point Capital, LP | 785,000 | 2.00% | $20.72M | −1,279,075 | 0.48% |
| State Street Corp | 685,945 | 1.75% | $18.10M | +486,442 | 0.00% |
| Geode Capital Management, LLC | 678,199 | 1.73% | $17.90M | +385,300 | 0.00% |
| 72 Investment Holdings, LLC | 667,778 | 1.70% | $17.62M | – | 35.27% |
| Northern Trust Corp | 632,701 | 1.61% | $16.70M | +159,298 | 0.00% |
| Millennium Management LLC | 558,320 | 1.42% | $14.73M | −263,662 | 0.01% |
| Point72 Asset Management, L.P. | 502,950 | 1.28% | $13.27M | −137 | 0.01% |
| Integral Health Asset Management, LLC | 500,000 | 1.27% | $13.20M | – | 0.52% |
| VR Adviser, LLC | 500,000 | 1.27% | $13.20M | – | 0.40% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 114 | 29M | 75.1% | 27 / 39 | 27 / 22 | 6M | 4M |
| Q1 2026 | 110 | 27M | 68.4% | 25 / 27 | 43 / 10 | 7M | 4M |
| Q4 2025 | 97 | 24M | 62.4% | 30 / 27 | 25 / 9 | 9M | 2M |
| Q3 2025 | 77 | 17M | 43.2% | 9 / 19 | 26 / 12 | 1M | 1M |
| Q2 2025 | 80 | 17M | 44.1% | 20 / 21 | 23 / 23 | 2M | 5M |
| Q1 2025 | 83 | 21M | 53.1% | 20 / 18 | 27 / 12 | 2M | 3M |
| Q4 2024 | 77 | 23M | 57.4% | 24 / 31 | 10 / 22 | 7M | 8M |
| Q3 2024 | 75 | 23M | 58.5% | 23 / 35 | 9 / 5 | 6M | 1M |
| Q2 2024 | 58 | 19M | 47.4% | 18 / 20 | 12 / 13 | 3M | 1M |
| Q1 2024 | 53 | 16M | 40.9% | 53 / 0 | 0 / 0 | 16M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
84 funds held ANRO in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ANRO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,011,881 | 2.58% | $26.70M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 663,352 | 1.69% | $17.51M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 346,618 | 0.88% | $9.15M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 287,033 | 0.73% | $7.77M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 240,404 | 0.61% | $6.34M | 0.04% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 228,057 | 0.58% | $6.02M | 0.05% | Jun 30, 2026 |
| iShares Biotechnology ETF | 221,513 | 0.56% | $5.85M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 190,203 | 0.48% | $5.02M | 1.17% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 182,834 | 0.47% | $4.95M | 0.43% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 165,070 | 0.42% | $4.47M | 0.39% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 138,181 | 0.35% | $2.77M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 88,048 | 0.22% | $2.32M | 0.15% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 70,748 | 0.18% | $1.87M | 4.20% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 63,570 | 0.16% | $1.72M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 48,959 | 0.12% | $1.29M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Amit Etkin | PRESIDENT AND CEO, Director | 833,949 | 2.13% | May 15, 2026 |
| Nicholas Conrad Smith | PRESIDENT AND CFO | 79,060 | 0.20% | Oct 5, 2026 |
| Adam Savitz | CHIEF MEDICAL OFFICER | 39,851 | 0.10% | Feb 13, 2026 |
| Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | – | – | Feb 13, 2026 |
| Andrew Craig Miller | Director | – | – | May 29, 2026 |
| Gwill York | Director | 23,917 | 0.06% | May 14, 2026 |
| Christopher Nixon Cox | Director | 588,898 | 1.50% | May 14, 2026 |
| Andrew Dreyfus | Director | – | – | May 14, 2026 |
| Husseini Manji | Director | – | – | May 14, 2026 |
| Ramiro Sanchez | Director | – | – | May 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Nicholas Conrad Smith PRESIDENT AND CFO | Oct 2, 2026 | Option exercise | +55,000 | $2.32 | $127.60K | 79,060 |
| Nicholas Conrad Smith PRESIDENT AND CFO | Sep 30, 2026 | Sale(10b5-1 plan) | −886 | $26.87 | $23.81K | 24,060 |
| Nicholas Conrad Smith PRESIDENT AND CFO | Sep 30, 2026 | Sale(10b5-1 plan) | −23,170 | $25.78 | $597.29K | 24,946 |
| Nicholas Conrad Smith PRESIDENT AND CFO | Sep 30, 2026 | Option exercise | +24,056 | $2.35 | $56.53K | 48,116 |
| Nicholas Conrad Smith PRESIDENT AND CFO | Sep 29, 2026 | Sale(10b5-1 plan) | −110,830 | $26.58 | $2.95M | 24,060 |
| Nicholas Conrad Smith PRESIDENT AND CFO | Sep 29, 2026 | Option exercise | +54,375 | $2.35 | $127.78K | 134,890 |
| Nicholas Conrad Smith PRESIDENT AND CFO | Sep 29, 2026 | Option exercise | +56,455 | $2.35 | $132.67K | 80,515 |
| Amit Etkin PRESIDENT AND CEO, Director | May 14, 2026 | Gift | −400,000 | – | – | 833,949 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | Mar 1, 2026 | Tax withholding | −2,806 | $19.69 | $55.25K | 24,060 |
| Amit Etkin PRESIDENT AND CEO, Director | Mar 1, 2026 | Tax withholding | −6,227 | $19.69 | $122.61K | 1,233,949 |
| Adam Savitz CHIEF MEDICAL OFFICER | Jul 10, 2024 | Buy | +2,931 | $13.22 | $38.75K | 39,851 |
| Adam Savitz CHIEF MEDICAL OFFICER | Jul 9, 2024 | Buy | +1,388 | $13.15 | $18.25K | 36,920 |
| Adam Savitz CHIEF MEDICAL OFFICER | Jul 9, 2024 | Buy | +10,681 | $12.53 | $133.83K | 35,532 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Mar 28, 2024 | Buy | +4,550 | $16.56 | $75.35K | 26,866 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Mar 28, 2024 | Buy | +1,600 | $15.80 | $25.28K | 22,316 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Mar 1, 2024 | Award | +19,153 | – | – | 20,716 |
| Amit Etkin PRESIDENT AND CEO, Director | Mar 1, 2024 | Award | +34,711 | – | – | 1,240,176 |
| Investment Group Ltd. Apeiron – | Feb 6, 2024 | Conversion | +251,881 | – | – | 251,881 |
| Investment Group Ltd. Apeiron – | Feb 6, 2024 | Conversion | +674,658 | – | – | 674,658 |
| Alpha Wave Global, LP 10% owner | Feb 6, 2024 | Conversion | +1,962,995 | – | – | 1,962,995 |
| Alpha Wave Global, LP 10% owner | Feb 6, 2024 | Conversion | +1,144,762 | – | – | 3,107,757 |
| Alpha Wave Global, LP 10% owner | Feb 6, 2024 | Buy | +600,000 | $16.00 | $9.60M | 3,707,757 |
| Adam Savitz CHIEF MEDICAL OFFICER | Feb 6, 2024 | Conversion | +7,851 | – | – | 7,851 |
| Adam Savitz CHIEF MEDICAL OFFICER | Feb 6, 2024 | Buy | +17,000 | $16.00 | $272.00K | 24,851 |
| Gwill York Director | Feb 6, 2024 | Conversion | +23,917 | – | – | 23,917 |
| Po Yu (Jeff) Chen Director | Feb 6, 2024 | Conversion | +39,259 | – | – | 39,259 |
| Po Yu (Jeff) Chen Director | Feb 6, 2024 | Conversion | +8,450 | – | – | 47,709 |
| Amit Etkin PRESIDENT AND CEO, Director | Feb 6, 2024 | Conversion | +11,777 | – | – | 1,202,340 |
| Amit Etkin PRESIDENT AND CEO, Director | Feb 6, 2024 | Buy | +3,125 | $16.00 | $50.00K | 1,205,465 |
| Christopher Nixon Cox Director | Feb 6, 2024 | Conversion | +588,898 | – | – | 588,898 |
| Christopher Nixon Cox Director | Feb 6, 2024 | Conversion | +126,755 | – | – | 715,653 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Feb 6, 2024 | Buy | +1,563 | $16.00 | $25.01K | 1,563 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alto Neuroscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,994 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nicholas Conrad Smith Officer | Sep 29, 2026 | 134,886 | $3.60M | Sep 29, 2026 | Exercise of Stock Options |
See a number that looks wrong?